Abstract:AIM:To evaluate the bioequivalence of ranitidine and bismuth derived from two compound preparations.METHODS:The bioavailability was measured in 20 healthy male Chinese volunteers following a single oral dose (equivalent to 200 mg of ranitidine and 220 mg of bismuth) of the test or reference products in the fasting state. Then blood samples were collected for 24 h. Plasma concentrations of ranitidine and bismuth were analyzed by high-performance liquid chromatography and inductively coupled plasma-mass spectrometry (ICP-MS), respectively. The non-compartmental method was used for pharmacokinetic analysis. Log-transformed C(max), AUC( (0-t) ) and AUC( (0-infinity) ) were tested for bioequivalence using ANOVA and Schuirmann two-one sided t-test. T(max) was analyzed by Wilcoxon's test.RESULTS:Various pharmacokinetic parameters of ranitidine derived from the two compound preparations, including C(max), AUC( (0-t)), AUC( (0-infinity)), T(max) and T((1/2)), were nearly consistent with previous observations. These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h). In addition, double-peak absorption profiles of ranitidine were found in some Chinese volunteers. For bismuth, those parameters derived from test and reference drug were as follows: C(max) (11.80 +/- 7.36 vs 11.40 +/- 6.55 microg/L), AUC( (0-t) ) (46.65 +/- 16.97 vs 47.03 +/- 21.49 microg/L per hour), T(max) (0.50 +/- 0.20 vs 0.50 +/- 0.20 h) and T((1/2)) (10.2 +/- 2.3 vs 13.0 +/- 6.9 h). Ninety percent of confidence intervals for the test/reference ratio of C(max), AUC( (0-t) ) and AUC( (0-infinity) ) derived from both ranitidine and bismuth were found within the bioequivalence acceptable range of 80%-125%. No significant difference was found in T(max) derived from both ranitidine and bismuth.CONCLUSION:The two compound preparations are bioequivalent and may be prescribed interchangeably.

Bioequivalence of Two Nizatidine Capsules in Healthy Volunteers

Bioequivalence of Domestic and Imported Nizatidine Formulations in Chinese Healthy Volunteers

Study on bioequivalence of cilostazol table in healthy volunteers

Studies on Bioequivalence of Indinavir Capsule in Healthy Volunteers

Studies on Bioequivalence of Ramipril Capsule in Healthy Volunteers

Evaluation of the bioequivalence and pharmacokinetics of two formulations of secnidazole after single oral administration in healthy volunteers

Bioequivalence of Two Cilnidipine Formulations in Healthy Chinese Volunteers

Bioequivalence Evaluation of Two Rabeprazole Enteric Coated Formulations in Healthy Chinese Volunteers

Pharmacokinetics and Bioequivalence of Ranitidine and Bismuth Derived from Two Compound Preparations

Bioequivalence of Pantoprazole Sodium Enteric-Coated Capsules in Human

Study on Relative Bioavailability of Two Flunarizine Hydrochloride Capsules

Evaluation of the Bioequivalence and Pharmacokinetics of Two Formulations of Rizatriptan after Single Oral Administration in Healthy Volunteers

Pharmacokinetics and bioequivalence of naproxen sodium sustained release tablets in healthy volunteers

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Pharmacokinetics and bioequivalence of roxithromycin capsules in healthy volunteers

Bioequivalence of ornidazole tablets in Chinese healthyvolunteers

Bioeguivalent Study of Two Fluconazole Capsules in Human Plasma

Bioequivalence of Domestic Azithromycin Granules in Healthy Volunteers

Bioavailability and Pharmacokinetics of Two Sustained Release Formulations of Mizolastine in Healthy Volunteers

Pharmacokinetic And Bioequivalence Study Of Three Oral Formulations Of Ambroxol 30 Mg: A Randomized, Three-Period Crossover Comparison In Healthy Volunteers

Bioequivalence of amlodipine besylate tablets in Chinese healthy volunteers